Metabolism openPub Date : 2023-11-11DOI: 10.1016/j.metop.2023.100262
Ihsan Almarzooqi, Hala Zakaria, Sofia Aleabova, Milena Caccelli, Cigdem Ozkan, Judith Skaf, Jestoni Bangayan, Dianne Catapang, Zeinab Jaafar, Ali Hashemi, Yousef Said
{"title":"Effectiveness of a hybrid technology enabled care model as measured by ICHOM standard set on established and managed type 2 patients already using medications: A RWE retrospective study","authors":"Ihsan Almarzooqi, Hala Zakaria, Sofia Aleabova, Milena Caccelli, Cigdem Ozkan, Judith Skaf, Jestoni Bangayan, Dianne Catapang, Zeinab Jaafar, Ali Hashemi, Yousef Said","doi":"10.1016/j.metop.2023.100262","DOIUrl":"10.1016/j.metop.2023.100262","url":null,"abstract":"<div><h3>Aims</h3><p>Diabetes is a pressing global health issue, demanding innovative strategies for improved treatment. However, traditional care often falls short of patient goals. To address this, digital health solutions, including smartphone apps and remote monitoring, have emerged as crucial in diabetes management. This study aims to assess a comprehensive intervention, combining remote continuous data monitoring (RCDM) with in-clinic care, for enhancing diabetes-related outcomes. Additionally, it seeks to evaluate the effectiveness of the digital RCDM component by comparing adherent and non-adherent patients.</p></div><div><h3>Methods</h3><p>Conducted in the United Arab Emirates, a retrospective study involved 89 patients primarily on anti-diabetic medications. They were split into two groups based on adherence to RCDM. Over time, significant improvements were observed across various parameters.</p></div><div><h3>Results</h3><p>Notably, patients exhibited weight loss (−4.0 ± 5.3, p < 0.001), reduced waist circumference (−4.74 ± 7.8, p < 0.001), lowered HbA1c levels (−1.00 ± 1.3, p < 0.001), decreased systolic BP (−3.1 ± 13.1, p = 0.035), and diminished diastolic BP (−3.4 ± 9.9, p = 0.002) annually. Furthermore, patients adhering to the GluCare model demonstrated substantial HbA1c reductions (−1.53 ± 1.5, p < 0.001), improved lipid profiles, notably decreased total Cholesterol (−16.6 ± 50.3, p = 0.034), and lowered LDL levels (−18.65 ± 42.6, p = 0.006).</p></div><div><h3>Conclusions</h3><p>The intervention model effectively managed T2D patients through a comprehensive approach, yielding notable improvements in HbA1c levels and other outcomes within a year. The study underscores the limitations of traditional care and reliance simply on pharmacotherapy, and emphasizes the need for a hyper-personalized, and continuous approach for T2D management.</p></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"20 ","pages":"Article 100262"},"PeriodicalIF":0.0,"publicationDate":"2023-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589936823000348/pdfft?md5=3c798d95e30bb640b0126ec21ce3375e&pid=1-s2.0-S2589936823000348-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135669983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Metabolism openPub Date : 2023-10-23DOI: 10.1016/j.metop.2023.100261
Yakubu Bene-Alhasan , David S. Siscovick , Joachim H. Ix , Jorge R. Kizer , Russell Tracy , Luc Djoussé , Kenneth J. Mukamal
{"title":"The determinants of fasting and post-load non-esterified fatty acids in older adults: The cardiovascular health study","authors":"Yakubu Bene-Alhasan , David S. Siscovick , Joachim H. Ix , Jorge R. Kizer , Russell Tracy , Luc Djoussé , Kenneth J. Mukamal","doi":"10.1016/j.metop.2023.100261","DOIUrl":"https://doi.org/10.1016/j.metop.2023.100261","url":null,"abstract":"<div><h3>Aim</h3><p>Non-esterified fatty acids (NEFA) are potential targets for prevention of key cardiometabolic diseases of aging, but their population-level correlates remain uncertain. We sought to identify modifiable factors associated with fasting and post-load NEFA levels in older adults.</p></div><div><h3>Methods</h3><p>We used linear regression to determine the cross-sectional associations of demographic, anthropometric, and lifestyle characteristics and medication use with serum fasting and post-load NEFA concentrations amongst community-dwelling older adults enrolled in the Cardiovascular Health Study (n = 1924).</p></div><div><h3>Results</h3><p>Fasting NEFA levels generally demonstrated a broader set of determinants, while post-load NEFA were more consistently associated with metabolic factors. Waist circumference and weight were associated with higher fasting and post-load NEFA. Cigarette smoking and caffeine intake were associated with lower levels of both species, and moderate alcohol intake was associated with higher fasting levels whereas greater consumption was associated with lower post-load levels. Unique factors associated with higher fasting NEFA included female sex, higher age, loop and thiazide diuretic use and calcium intake, while factors associated with lower fasting levels included higher educational attainment, beta-blocker use, and protein intake. Hours spent sleeping during the daytime were associated with higher post-load NEFA, while DASH score was associated with lower levels.</p></div><div><h3>Conclusion</h3><p>Fasting and post-load NEFA have both common and unique modifiable risk factors, including sociodemographics, anthropometric, medications, and diet. Post-load NEFA were particularly sensitive to metabolic factors, while a broader range of determinants were associated with fasting levels. These factors warrant study as targets for lowering levels of NEFA in older adults.</p></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"20 ","pages":"Article 100261"},"PeriodicalIF":0.0,"publicationDate":"2023-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589936823000336/pdfft?md5=767698879f156b12350e540ac6329960&pid=1-s2.0-S2589936823000336-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"92044499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Hepatoprotective effect of hydromethanol extract of Otostegia integrifolia benth leaves in isoniazid and rifampicin induced Swiss albino mice","authors":"Endalkachew Gugsa, Tewodros Shibabaw Molla, Tesfahun Bekele, Tadesse Asmamaw Dejenie","doi":"10.1016/j.metop.2023.100255","DOIUrl":"https://doi.org/10.1016/j.metop.2023.100255","url":null,"abstract":"<div><h3>Introduction</h3><p>Drug-induced liver injury is the most common cause of acute liver failure. Off-Target effect “hepatotoxicity “frequently detected during clinical examination of patients on <em>anti</em>-Tb medication particularly isoniazid (INH), and rifampin (RMP). However, there is no any treatment option against isoniazid and rifampicin induced hepatotoxicity. It is, therefore, necessary to search for effective affordable and safe drugs from medicinal plants for the prevention of liver toxicity caused by isoniazid and rifampicin. The aim the current study is to evaluate hepatoprotective effect of hydro methanol extract from <em>Otostegia integrifolia</em> leaves in isoniazid and rifampicin-induced hepatotoxicity in Swiss albino mice.</p></div><div><h3>Methods</h3><p><em>O. integrifolia</em> leaves powder was macerated in hydromethanol and thirty Swiss albino mice 29.0–40.6 g were grouped in to five groups. Group I were given 20 ml/kg distilled water, group II were given 100 mg INH and 150 mg RIF per kg body weight. Group III, group IV, and group V were given 200 mg extract, 400 mg extract, and 100 mg of <em>N</em>-acetyl cysteine respectively per kg 1hr before induction with 100 mg INH plus 150 mg RIF per kg. The treatments were followed for 14 days. On the 15th day, all mice were anaesthetized with diethyl ether; blood samples were collected for the assessment liver enzyme and function test.</p></div><div><h3>Results</h3><p>Group II mice's serum ALT, AST and total bilirubin levels were significantly increased and serum total protein and albumin levels were significantly decreased as compared with group I mice. The groups of mice treated with <em>O. integrifolia</em> at a dose of 400 mg/kg and <em>N</em>-acetyl cysteine AST, ALT and total bilirubin level were significantly decreased; and total protein and albumin levels were significantly (P < 0.05) increased as compared with group II. The liver index of the group IV showed decreased (P < 0.05) as compared to the group II.</p></div><div><h3>Conclusion</h3><p>Evidence from our study revealed that the hydromethanol extract of O. integrifolia has a hepatoprotective effect against isoniazid and rifampicin-induced hepatotoxicity in Swiss Albino mice. This protective effect of O. integrifolia extract may be based on its metal ion reducing power, free radical scavenging activity, and anti-inflammatory activity and could be used as a potential therapeutic option.</p></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"20 ","pages":"Article 100255"},"PeriodicalIF":0.0,"publicationDate":"2023-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589936823000270/pdfft?md5=b681bad02f9bb8eb314cd91d460468fe&pid=1-s2.0-S2589936823000270-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91958635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Metabolism openPub Date : 2023-10-13DOI: 10.1016/j.metop.2023.100260
Robert J. Castro, Kazandra Pedroza, Mee Young Hong
{"title":"The effects of mango consumption on vascular health and immune function","authors":"Robert J. Castro, Kazandra Pedroza, Mee Young Hong","doi":"10.1016/j.metop.2023.100260","DOIUrl":"https://doi.org/10.1016/j.metop.2023.100260","url":null,"abstract":"<div><h3>Objectives</h3><p>Heart disease, caused by atherosclerosis, is the leading cause of death. Maintaining vascular integrity is crucial to reducing atherosclerosis risk. Mangos are rich in fiber, vitamins, minerals, and phytochemicals that may offer cardioprotective and immune-boosting benefits. However, their effects on the vasculature and immune system in adults with overweight and obesity remain unclear. The objective of this study was to investigate the effects of mango consumption on vascular health and immune function in adults with overweight and obesity.</p></div><div><h3>Methods</h3><p>In a 12-week, crossover study, 27 overweight and obese participants consumed either 100 kcals of mangos daily or isocaloric low-fat cookies daily. Fasting blood samples were collected at baseline, week 4, and week 12 and analyzed for vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1), P-selectin, E-selectin, sCD4, sCD8, sCD3E, and sCD45, tumor necrosis factor-alpha (TNF-α), catalase (CAT), glutathione peroxidase (GPx), and superoxide dismutase (SOD).</p></div><div><h3>Results</h3><p>Mango consumption significantly decreased VCAM-1 between baseline and week 4 (P = 0.046) and week 12 (P = 0.004). CAT increased between baseline and week 12 (P = 0.035) with mango consumption. GPx increased at week 12 compared to baseline and week 4 (P < 0.05). At week 12, SOD was higher after mango consumption compared to low-fat cookie consumption (P = 0.046). There were no significant differences in ICAM-1, P-selectin, E-selectin, sCD4, sCD8, sCD3E, sCD45 or TNF-α concentrations (P > 0.05 for all non-significant results).</p></div><div><h3>Conclusions</h3><p>This study suggests that 100 kcals of mangos may benefit the integrity of the vasculature by reducing VCAM-1 and increasing SOD, CAT, and GPx levels. Mangos can be an alternative snack for improving atherosclerosis and oxidative stress risk factors.</p></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"20 ","pages":"Article 100260"},"PeriodicalIF":0.0,"publicationDate":"2023-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50173529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Metabolism openPub Date : 2023-09-21DOI: 10.1016/j.metop.2023.100257
Nusrat Zahan Bhuiyan , Md. Kamrul Hasan , Zimam Mahmud , Md. Sabbir Hossain , Atiqur Rahman
{"title":"Prevention of Alzheimer's disease through diet: An exploratory review","authors":"Nusrat Zahan Bhuiyan , Md. Kamrul Hasan , Zimam Mahmud , Md. Sabbir Hossain , Atiqur Rahman","doi":"10.1016/j.metop.2023.100257","DOIUrl":"10.1016/j.metop.2023.100257","url":null,"abstract":"<div><h3>Introduction</h3><p>This exploratory review article describes about the genetic factors behind Alzheimer's disease (AD), their association with foods, and their relationships with cognitive impairment. It explores the dietary patterns and economic challenges in AD prevention.</p></div><div><h3>Methods</h3><p>Scopus, PubMed and Google Scholar were searched for articles that examined the relationships between Diets, Alzheimer's Disease (AD), and Socioeconomic conditions in preventative Alzheimer's disease studies. Graphs and Network analysis data were taken from Scopus under the MeSH search method, including words, Alzheimer's, APoE4, Tau protein, APP, Amyloid precursor protein, Beta-Amyloid, Aβ, Mediterranean Diet, MD, DASH diet, MIND diet, SES, Socioeconomic, Developed country, Underdeveloped country, Preventions. The network analysis was done through VOS viewer.</p></div><div><h3>Results</h3><p>Mediterranean diet (MD) accurately lowers AD (Alzheimer's Disease) risk to 53% and 35% for people who follow it moderately. MIND scores had a statistically significant reduction in AD rate compared to those in the lowest tertial (53% and 35% reduction, respectively). Subjects with the highest adherence to the MD and DASH had a 54% and 39% lower risk of developing AD, respectively, compared to those in the lowest tertial. Omega-6, PUFA, found in nuts and fish, can play most roles in the clearance of Aβ. Vitamin D inhibits induced fibrillar Aβ apoptosis. However, the high cost of these diet components rise doubt about the effectiveness of AD prevention through healthy diets.</p></div><div><h3>Conclusion</h3><p>The finding of this study revealed an association between diet and the effects of the chemical components of foods on AD biomarkers. More research is required to see if nutrition is a risk or a protective factor for Alzheimer's disease to encourage research to be translated into therapeutic practice and to clarify nutritional advice.</p></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"20 ","pages":"Article 100257"},"PeriodicalIF":0.0,"publicationDate":"2023-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ac/12/main.PMC10539673.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41175121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Metabolism openPub Date : 2023-09-15DOI: 10.1016/j.metop.2023.100256
Maya Fayfman , Andrew T. Gewirtz , Clara Delaroque , Gerardo Blanco , Seid Gibanica , Shanthi Srinivasan , Benoit Chassaing
{"title":"Microbiome differences related to metformin intolerance among Black individuals with diabetes, a pilot cross-sectional study","authors":"Maya Fayfman , Andrew T. Gewirtz , Clara Delaroque , Gerardo Blanco , Seid Gibanica , Shanthi Srinivasan , Benoit Chassaing","doi":"10.1016/j.metop.2023.100256","DOIUrl":"https://doi.org/10.1016/j.metop.2023.100256","url":null,"abstract":"<div><h3>Aims</h3><p>Metformin is the broadly accepted the first-line medication for diabetes. Its use, however, is limited by gastrointestinal side effects present in approximately 25% of patients. This study aimed to better understand the interplay between metformin intolerance and gut microbiota among Black individuals with diabetes.</p></div><div><h3>Methods</h3><p>We performed a cross-sectional study among 29 Black individuals living with diabetes with or without metformin intolerance. Participants with mean age 59±11, 58% female, were stratified into three groups: 1)intolerant: metformin intolerance in the past, not on metformin; 2)partially intolerant: mild to moderate gastrointestinal symptoms, currently taking metformin 3)tolerant: using metformin without symptoms. We collected and analyzed rectal swabs and analyzed microbiota composition using V3–V4 regions of the 16s rRNA.</p></div><div><h3>Results</h3><p>Metformin intolerant subjects trended towards having greatest alpha diversity, followed by tolerant and partially tolerant (Intolerant:4.9; Tolerant:4.2; Partially tolerant:3.9). Mean difference in alpha diversity for intolerant versus partially tolerant was 1.0 (95% CI-0.1,2.1) and intolerant versus tolerant were 0.7 (95% CI -0.4,1.8).</p></div><div><h3>Conclusion</h3><p>This was the first study to evaluate the role of microbiota and metformin intolerance among Black individuals. We report on differences in alpha diversity as well as microbiota composition.</p></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"20 ","pages":"Article 100256"},"PeriodicalIF":0.0,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50173571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Metabolism openPub Date : 2023-09-01DOI: 10.1016/j.metop.2023.100253
Candice Stamper, Sama Safadi, Andrew Gehr, Pia Asuncion, Mee Young Hong
{"title":"Effects of fresh vs dried mango consumption on satiety and postprandial glucose in healthy adults","authors":"Candice Stamper, Sama Safadi, Andrew Gehr, Pia Asuncion, Mee Young Hong","doi":"10.1016/j.metop.2023.100253","DOIUrl":"10.1016/j.metop.2023.100253","url":null,"abstract":"<div><p>Mango is a widely favored fruit that offers high nutritional value. Mango has been studied to examine its influence on postprandial glucose, but few studies have used fresh mango compared to dried mango to measure blood glucose and satiety after consumption. Therefore, the objective of the present study was to investigate the effects of fresh versus dried mango consumption on satiety and postprandial glucose. A crossover design was implemented where 34 healthy adults (29 females and 5 males; 25.0 ± 6.0 years; BMI 23.8 ± 4.3 kg/m<sup>2</sup>) consumed either 100 kcal of fresh mango, dried mango, or white bread on three separate occasions. Following consumption, satiety was assessed every 15 min for 90 min and blood glucose was assessed every 30 min for 90 min. Consumption of fresh mango results showed a significant increase in satiety (tendency of greater fullness (P = 0.073) and less desire to eat (P < 0.05)) in participants. Fresh mango exhibited a more efficient decrease in postprandial glucose levels (P < 0.05) compared to dried mango or white bread, and fresh mango promoted a greater stability in blood glucose. Dried mango consumption also significantly lowered postprandial glucose compared to white bread (P < 0.05). These results suggest that fresh mango consumption may be beneficial in improving satiety responses and postprandial glucose control when compared to its dried alternative or white bread. The results of the study may help guide individuals who are overweight or obese and/or have type 2 diabetes by altering their food choices that ultimately could improve their health.</p><p>ClinicalTrials.gov Identifier: NCT03956602.</p></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"19 ","pages":"Article 100253"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e2/1b/main.PMC10374964.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10267328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Comparison of circulating lipid profiles, D-dimer and fibrinogen levels between hypertensive patients with and without stroke","authors":"Endeshaw Chekol Abebe , Misganaw Asmamaw Mengstie , Mohammed Abdu Seid , Natnael Atnafu Gebeyehu , Getachew Asmare Adella , Gizachew Ambaw Kassie , Molalegn Mesele Gesese , Kirubel Dagnaw Tegegne , Denekew Tenaw Anley , Sefineh Fenta Feleke , Melkamu Aderajew Zemene , Anteneh Mengist Dessie , Natnael Amare Tesfa , Natnael Moges , Ermias Sisay Chanie , Yenealem Solomon Kebede , Berihun Bantie , Tadesse Asmamaw Dejenie","doi":"10.1016/j.metop.2023.100252","DOIUrl":"10.1016/j.metop.2023.100252","url":null,"abstract":"<div><h3>Background</h3><p>Stroke is one of the leading causes of global mortality and disability, particularly in hypertensive patients. This study aimed to compare lipid profile, fibrinogen, and D-dimer levels between hypertensive patient with and without stroke.</p></div><div><h3>Methods</h3><p>This was a facility-based cross-sectional study conducted from November 2022 to January 2023 among 115 hypertensive patients (70 patients without stroke and 45 with stroke) who had follow-up at Yikatit 12 Hospital Medical College, Ethiopia. All data analyses were done using SPSS version 25.0 and comparisons of variables between groups were made using the Chi-square test, independent sample <em>t</em>-test, and Mann-Whitney <em>U</em> test. Multiple logistic regression analysis was done to identify predictors of stroke among hypertensive patients. A p-value <0.05 was assumed to be statistically significant for all statistical tests.</p></div><div><h3>Results</h3><p>Significantly elevated levels of TC, LDL-C, D-DI, and fibrinogen were observed in the stroke group than in the non-stroke group (p-value<0.05). The mean values of TC, D-DI, and fibrinogen were significantly higher in patients with ischemic stroke compared to those with hemorrhagic stroke. Duration of hypertension (AOR: 1.21; CI: 1.10, 2.09), TC (AOR:1.07; CI: 1.01, 1.22), D-DI (AOR: 1.15; CI: 1.05, 1.69) and fibrinogen (AOR:1.19; CI: 1.10, 2.89) were identified to be independent predictors of stroke in hypertensive patients.</p></div><div><h3>Conclusion</h3><p>The circulating levels of TC, LDL-C, D-DI and fibrinogen in hypertensive patients with stroke were significantly higher than in those without stroke. But only TC, D-DI, and fibrinogen were found to be predictors of stroke in hypertensives. Considerably higher TC, D-DI, and fibrinogen levels were also seen in patients with ischemic stroke than in those with hemorrhagic stroke. This confirms the key roles of dyslipidemia (hypercholesterolemia) and aberrant hemostatic activation to stroke development, notably ischemic stroke.</p></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"19 ","pages":"Article 100252"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/aa/76/main.PMC10407734.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9963562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Evaluation of liver function biomarkers, blood pressure, and anthropometric parameters among chronic kidney disease patients: Laboratory-based cross-sectional study in Northwest Ethiopia","authors":"Melaku Mekonnen Agidew , Endeshaw Chekol Abebe , Zelalem Tilahun Muche , Misganaw Asmamaw Mengstie , Anemut Tilahun Mulu , Fitalew Tadele Admasu , Awgichew Behaile Teklemariam , Edgiet Abebe Zewde , Gelagey Baye Temesgen , TeklieMengie Ayele , Achenef Bogale Kassie , Nega Dagnew Baye , Tadesse Asmamaw Dejenie","doi":"10.1016/j.metop.2023.100254","DOIUrl":"10.1016/j.metop.2023.100254","url":null,"abstract":"<div><h3>Background</h3><p>Chronic kidney disease (CKD) is a non-communicable disease leading to a progressive decline in kidney functions and complications like liver disorders. Serum levels of liver parameters such as aminotransferases and bilirubin are important biomarkers for the diagnosis of liver diseases. Studies on the effect of CKD with and without end-stage renal disease (ESRD) on the levels of liver biomarkers in Ethiopia are limited. Hence, this study aimed to assess liver biomarkers, blood pressure (BP) and anthropometric indices in CKD patients attending a renal clinic of Felege Hiwot Comprehensive Specialized Hospital(FHCSH) in Bahir Dar, Ethiopia.</p></div><div><h3>Method</h3><p>A hospital-based cross-sectional study was conducted among 100 CKD patients attending the renal clinic of FHCSH in Bahir Dar, Ethiopia. Data were collected using a structured questionnaire through face-to-face interview. BP and anthropometric parameters were measured based on the standard procedures. About 5 ml of serum was used to analyzeliver parameter using automated chemistry analyzer. All data analyses such as independent sample t-testand one-way ANOVA were done using SPSS version 25.0. Besides, Pearson’s correlation analysis and multiple linear regression were done to identify predictors of liver biomarkers in CKD patients. P-value< 0.05 were considered statistically significant.</p></div><div><h3>Results</h3><p>The mean serum levels of AST and ALT were significantly lower in CKD patients under dialysis when compared to CKD patients with no dialysis (<em>p</em> < 0.05). These enzymes were positively and negatively correlated with eGFRand the severity of CKD, respectively. However, there were no significant differences in bilirubin level between different stages of CKD. There was also a significant increase (p < 0.05) in the levels of AST and ALT with BMI.There was also a significant rise of SBP and DBP in CKD patients under dialysis compared to CKD patients not in dialysis.</p></div><div><h3>Conclusion</h3><p>Aminotransferases were significantly lower in CKD patients undergoing dialysis than in CKD patients not undergoing dialysis, warranting the need fora separate standard reference ranges or using other diagnostic criteria to diagnose liver comorbidities in CKD patients. The levels of AST and ALT in CKD patients were also significantly increased with BMI. Besides, BP was significantly elevated with the severity of CKD, indicating the more advanced the CKD is, the higher BP.</p></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"19 ","pages":"Article 100254"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ad/31/main.PMC10480547.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10189856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Metabolism openPub Date : 2023-09-01DOI: 10.1016/j.metop.2023.100251
Akira Mima, Rina Lee, Ami Murakami, Hidemasa Gotoda, Ryosuke Akai, Sayumi Kidooka, Takahiro Nakamoto, Suguru Kido, Shinji Lee
{"title":"Effect of finerenone on diabetic kidney disease outcomes with estimated glomerular filtration rate below 25 mL/min/1.73 m2","authors":"Akira Mima, Rina Lee, Ami Murakami, Hidemasa Gotoda, Ryosuke Akai, Sayumi Kidooka, Takahiro Nakamoto, Suguru Kido, Shinji Lee","doi":"10.1016/j.metop.2023.100251","DOIUrl":"https://doi.org/10.1016/j.metop.2023.100251","url":null,"abstract":"<div><h3>Background</h3><p>In the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease trial, finerenone reduced the risk of cardiovascular events in patients with chronic kidney disease (CKD) and type 2 diabetes, while in the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease trial, it improved renal and cardiovascular outcomes in patients with advanced CKD. However, no previous studies have assessed patients with CKD and type 2 diabetes with an estimated glomerular filtration rate (eGFR) below 25 mL/min/1.73 m<sup>2</sup></p></div><div><h3>Methods</h3><p>Nine patients with CKD and type 2 diabetes who received finerenone 10 mg/day were analyzed retrospectively. Changes in eGFR, urinary protein, and serum potassium levels were studied from 1 year before administration of finerenone until 6 months after administration.</p></div><div><h3>Results</h3><p>The mean baseline eGFR slope was −7.63 ± 9.84 (mL/min/1.73 m<sup>2</sup>/year). After finerenone treatment, the mean eGFR slope significantly improved −1.44 ± 3.17 (mL/min/1.73 m<sup>2</sup>/6 months, <em>P</em>=0.038). However, finerenone treatment did not significantly reduce proteinuria. Furthermore, finerenone did not increase serum potassium levels.</p></div><div><h3>Conclusions</h3><p>Patients treated with finerenone showed a significantly slower decline in eGFR. Furthermore, aside from the present study, no reports have indicated the effectiveness of finerenone in patients with advanced CKD with an eGFR below 25 mL/min/1.73 m<sup>2</sup>. As confirmed in our clinical trials, the finding that finerenone is effective in a wide range of renal functions can be generalized to clinical practice. However, sample size in this study was small. Thus, further large-scale investigations will be needed.</p></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"19 ","pages":"Article 100251"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50199253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}